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associated with signiﬁcantly lower inpatient ($4,212 vs $7,532,
p < 0.0001), outpatient ($9,501 vs $12,885, p < 0.0001), and
emergency room costs ($82 vs $131, p < 0.0001) and signiﬁcantly
higher drug costs ($6,885 vs $5,936, p < 0.0001). Similarly, the
use of exenatide compared to insulin glargine was also associated
with signiﬁcantly lower diabetes-related inpatient ($2172 vs
$3538, p < 0.0001) and outpatient costs ($2739 vs $3249,
p < 0.0001) and signiﬁcantly higher diabetes-related drug costs
($3160 vs $2424, p < 0.0001). CONCLUSIONS: Use of
exenatide, compared to insulin glargine, was found to be associ-
ated with signiﬁcantly lower annual total direct medical costs and
total diabetes related medical costs even though diabetes related
and total drug costs were higher.
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OBJECTIVES: Compare costs among patients with type 2 dia-
betes (T2D) treated with either exenatide or sitagliptin, novel
incretin therapies with differing clinical effectiveness.
METHODS: Data from September 2004 to September 2007
were obtained from a large, retrospective, claims database. Data
from intent-to-treat cohorts of adults with T2D who initiated
therapy on either exenatide (N = 1614) or sitagliptin (N = 2482)
and who did not use the other medication in the six-month
follow-up period were examined. Total medical costs and total
diabetes-related medical costs were estimated using stepwise
multivariate regressions. Major cost components were also
examined using either stepwise multivariate regressions or a two-
part model that controlled for the probability of using the
service. Smearing estimates were used to transform estimated log
costs into costs. The analyses controls for the potential impact of
patient demographics, general health, prior resource use, comor-
bidities, and timing of treatment initiation. RESULTS: Initiation
on therapy with exenatide, compared to sitagliptin, was associ-
ated with signiﬁcantly lower total direct medical costs ($8736
vs $9995, p < 0.0001) and total diabetes-related medical
costs ($3841 vs $4002, p < 0.0001). Initiation of therapy with
exenatide compared to sitagliptin was also associated with sig-
niﬁcantly lower inpatient ($745 vs $3624, p < 0.0001), outpa-
tient ($4269 vs $5942, p < 0.0001), drug ($3467 vs $3611,
p < 0.0001) and emergency room costs ($16 vs $44, p < 0.0001).
Similarly, the use of exenatide compared to sitagliptin was
associated with signiﬁcantly lower diabetes-related inpatient
($448 vs $1847, p < 0.0001) and drug costs ($1,677 vs $1743,
p < 0.0001). CONCLUSIONS: Use of exenatide compared to
sitagliptin over six months is associated with signiﬁcantly lower
total direct medical costs and total diabetes-related medical costs.
In addition, exenatide was associated with signiﬁcantly lower
total inpatient, outpatient, drug, and emergency room costs and
signiﬁcantly lower diabetes-related inpatient and drug costs.
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OBJECTIVES: Vildagliptin is an alternative option to glitazones
when treatment intensiﬁcation is required due to loss of glycae-
mic control. Our analysis compares the clinical and cost-utility
effects of these alternative treatments. METHODS: The analysis
uses the Novartis 24-week 2354 study results comparing vilda-
gliptin 50mg BID to pioglitazone 30mg qd. The Shefﬁeld Type 2
Diabetes Model, a patient-level disease management model,
simulates use of therapies, clinical events, treatment of compli-
cations and mortality. Costs, including the £1.13 vildagliptin
daily price and £1.20 for pioglitazone, and quality-of-life (QoL)
effects, including those related to complications and weight effect
of therapies, were aggregated to obtain the incremental cost
per QALY. Uncertainty around key parameters, such as weight
effects and long-term HbA1c trends, was explored using proba-
bilistic sensitivity analysis and scenarios. RESULTS: Assuming
equal long-term HbA1c trends, the point estimate suggests that
vildagliptin is cost effective compared to pioglitazone with a cost
saving of £88 and reduction in QALYs of 0.0006. The marginal
net beneﬁt of vildagliptin compared to pioglitazone is £77 (95%
C.I. -23 to 177) with a 62% likelihood that vildagliptin is cost
effective at a UK notional £20,000 cost/QALY threshold. The
main driver is the cheaper cost of vildagliptin. There is a small
QALY loss due to fewer CHD events with pioglitazone arising
from its superior lipid effects, although this is mitigated by the
QALY gain due to the weight neutrality of vildagliptin. The
long-term HbA1c trends are highly important but uncertain
assumptions, and conclusions about the cost effectiveness could
change if evidence for different trends emerged. CONCLU-
SIONS: The expected differences in lifetime costs and QALYs
between vildagliptin and pioglitazone are small, with consider-
able uncertainty around key parameters. Results suggest a 62%
likelihood that vildagliptin is cost effective compared to piogli-
tazone at a £20,000 cost/QALY threshold assuming similar long-
term HbA1c trends.
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OBJECTIVES: The aim of this analysis was to evaluate the
long-term clinical and economic outcomes associated with
insulin detemir and Neutral Protamine Hagedorn (NPH) insulin
in combination with mealtime insulin aspart in patients with type
1 diabetes in the Belgian, French, German, Italian and Spanish
settings. METHODS: A published and validated computer simu-
lation model of diabetes (CORE Diabetes Model) was used to
make long-term projections of life-expectancy, quality-adjusted
life expectancy and direct medical costs. The analysis was based
on patient characteristics and treatment effects from a 2-year,
multi-national, open-label, randomized, controlled trial. In the
trial, insulin detemir was associated with signiﬁcant improve-
ments in glycemic control after 24 months (HbA1c 7.36% versus
7.58%, mean difference -0.22%, P = 0.022) and major hypogly-
cemic events (69% risk reduction, P = 0.001) versus NPH.
Patients treated with detemir gained less weight (1.7 versus 2.7
kg, P = 0.024). Events were projected for a time horizon of 50
years. RESULTS: Basal-bolus therapy with insulin detemir was
projected to improve quality-adjusted life expectancy by 0.45
years (7.04 versus 6.59 years) versus NPH in the German setting.
Similar improvements were observed in the other countries
(Belgium +0.52, France +0.55, Italy +0.58 and Spain +0.40
years). Insulin detemir was associated with cost savings in
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